BioMap has completed a $100 million Series A round of financing

36Kr has learned that recently, AI Native biopharmaceutical company "BioMap" announced the completion of its Series A+ financing. So far, the total financing of the company's Series A round has exceeded 100 million US dollars. This round of financing is led by China Life Capital, with old shareholder Shanghai Biomedical Fund increasing its investment again. Multiple institutions including China Development Bank Technology Innovation, Ruili Investment, Guofang Venture Capital and leading biomedical industrial parties participated in the follow-on investment. Old shareholder Fortune Capital continued to increase its stake, and Index Capital continued to act as the exclusive financial advisor. The funds raised in this round will be mainly used for the continuous iteration of two micro-world models, GeoFlow (molecular level) and GeoCell (cellular level), the expansion of high-throughput automated laboratories, and the commercial implementation of self-developed drug pipelines.